uniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIKSEC APISEC submissions APIRetrieved 2026-05-20 · Filing chronology and company identitySEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · Financial statement cross-checksAnnual reportFY2025 Form 10-K filed 2026-03-022026 · Annual business, risk and financial baselineQuarterly reportForm 10-Q filed 2026-05-052026 · Latest interim financial baselineCurrent reportForm 8-K filed 2026-05-052026 · Recent filing chronologyProxy statementDEF 14A filed 2026-04-272026 · Governance and incentive context